Latest publications

AdnaTest ProstateCancerPanel AR-V7

  • Horie S. et al. (2020)
    Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. PLOS ONE
  • Vlaeminck-Guillem V. et al. (2019)
    Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. European Urology Oncology
  • Cappelletti V. et al. (2019)
    Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. Cancers
  • Clark E. et al. (2019)
    Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ
  • Antonarakis E. et al. (2019)
    Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol
  • Hench I. et al. (2019)
    Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial). Cancers
  • Zhang T. et al. (2019)
    The Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. ScienceDirect 
  • Josefsson A. et al. (2018)
    Circulating tumor cells mirror bone metastatic phenotype in prostate cancer. Oncotarget
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.